QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT06917092
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • QL1706 combined with chemotherapy ± Bevacizumab — DRUG
    * Drug: QL1706: 5 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first. * Drug: Chemotherapy: physician's choice chemotherapy for 3-6 cycles. * Drug: Bevacizumab (optional): 15 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first.

Study Details

This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.

Key Dates

First listed
Apr 8, 2025
Start date
May 1, 2025
Status verified
Mar 2025
Primary completion
Apr 30, 2027
Completion
Apr 30, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: QL1706 Combination Therapy
    QL1706 Combination Therapy in Immunotherapy-Pretreated Recurrent or Metastatic Endometrial Carcinoma

Primary Outcome Measure

Objective response rate (ORR) - Investigator assessment [ Time Frame: Up to 5 years ]

Central Contacts

Related Studies